TAIPEI, July 9, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced the appointment of Brian J. Groch as Chief Commercial Officer, effective July 1, 2026. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.
Brian is a seasoned healthcare executive with more than 30 years of industry background and experience in the pharmaceutical industry including multiple leadership roles at Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. He has many years of experience leading global market access strategies and commercial executions, successfully driving the commercialization and market adoption of various treatments across multiple disease areas. Prior to his executive roles, he worked as a Director of Health Policy and Regional Sales at Novartis and spent more than 13 years working for Merck on large-scale commercial and marketing management programs.
"I am pleased to announce that Brian J. Groch has joined Foresee as Chief Commercial Officer," said Dr. Ben Chien, Ph.D., Chairman and Chief Executive Officer of Foresee Pharmaceuticals. "Brian will lead Foresee in building a commercial team to launch the FP-001 for the treatment of CPP patients in the U.S., Taiwan, and potentially other selected countries. We are excited that Foresee will build upon our R&D success and transition into a new phase of building direct commercialization capabilities."
Foresee is systematically executing its global regulatory roadmap for the CPP program:
U.S. Market: The New Drug Application (NDA) submission to the U.S. FDA is targeted for the second half of 2026.
Global Markets: Marketing authorization applications will be submitted to health agencies in Taiwan and other strategic territories between late 2026 and the first half of 2027.
Ongoing Initiatives: Engage in pre-NDA meetings and regulatory discussions to ensure a streamlined review process.
About Central Precocious Puberty (CPP)
Central Precocious Puberty is a condition characterized by premature activation of the pituitary-gonadal axis, leading to early puberty. If left untreated, CPP can result in accelerated bone maturation and reduced final adult height, as well as significant psychosocial challenges for affected children. The current standard of care involves treatment with GnRH agonists to halt pubertal progression.